Biomea’s early-stage diabetes drug put on full clinical hold, stock crashes

Bio­mea Fu­sion’s Phase 1/2 co­va­lent menin in­hibitor pro­gram in di­a­betes has been placed on full clin­i­cal hold due to “pos­si­ble” drug-re­lat­ed he­pa­to­tox­i­c­i­ty.

Liv­er en­zyme el­e­va­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.